Keren Haruvi Named Chair of the Association for Accessible Medicines Board of Directors

WASHINGTON D.C. (January 23, 2024) — The Board of Directors of the Association for Accessible Medicines (AAM) has named as its new Chairperson, Keren Haruvi, President of Sandoz North America, who was elected for a one-year term.

“I am honored and excited about the opportunity to be the Association for Accessible Medicines Board of Directors Chair in 2024,” said Keren Haruvi, Chairperson of the AAM Board of Directors. “During my tenure, my focus will be working with key stakeholders to promote predictable and sustainable access to high quality generic and biosimilar medicines for America’s patients.  This is especially important as we recognize the 40th anniversary of the Hatch-Waxman Act. Since its passage in 1984, generics market share drastically increased patient access to medicines that may have previously been out of reach. Together with the AAM Board, its membership and staff, we will strengthen AAM’s efforts to impact the generic and biosimilar industries, and work to remove obstacles that impede patient access to generics and biosimilar medicines.”

 Prior to her current role at Sandoz, Haruvi served as Global Head of M&A for Novartis after 14 years at Teva Pharmaceuticals.

David Gaugh, Interim President and CEO of AAM stated, “Keren has served AAM as vice chair and then as Chair, fulfilling a vacancy in late 2023. Keren has demonstrated great leadership as a member representative for our association. We look forward to her continued leadership in the coming year as AAM continues its vital work to highlight the value and importance of generic and biosimilar medications to American patients and the overall healthcare ecosystem.”

AAM also elected Bob Hoffman, Chief Commercial Officer of US Generics for Lupin Pharmaceuticals, Inc. as Vice Chair of the Board, and Jeff Burd, President & CEO, North America, Ajanta Pharma USA Inc. as Treasurer.


For media inquiries, contact the Communications department at

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 17.5 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.